Enzyme News and Research

RSS

Study: Blocking energy pathway helps reduce graft-versus-host disease

MUSC Hollings Cancer Center researchers identified that blocking an alternative energy pathway for T-cells after hematopoietic stem cell transplant helps reduce graft-versus-host disease (GVHD) in an animal model of leukemia.

5 Nov 2020

Pre-existing anti-IFN autoantibodies may worsen COVID-19 in lupus patients

“Our observations suggest that the presence of these autoantibodies may predispose SLE patients to infection with SARS-CoV-2 with a more severe presentation and represent an additional risk factor in this patient population,” write Sarthak Gupta and colleagues from the National Institute of Arthritis and Musculoskeletal and Skin Diseases in Bethesda, Maryland.

5 Nov 2020

Mice study finds gene that controls food cravings, desire to exercise

National Institutes of Health researchers have discovered a gene in mice that controls the craving for fatty and sugary foods and the desire to exercise.

5 Nov 2020

Stanford researchers create a highly automated device that can detect COVID-19 in 30 minutes

Throughout the pandemic, infectious disease experts and frontline medical workers have asked for a faster, cheaper and more reliable COVID-19 test.

5 Nov 2020

Study describes the effects of a DPP3-knockout on the renin-angiotensin system

The role of the enzyme dipeptidyl peptidase 3 in the blood pressure-regulating renin-angiotensin system was investigated in the inter-university cooperation project BioTechMed-Graz. The results could pave the way for new therapies for cardio-renal diseases.

5 Nov 2020

Green tea and some fruit juices inhibit SARS-CoV-2 in vitro

Green tea, chokeberry juice, and pomegranate juice killed flu and SARS-CoV-2 viruses when incubated with the viruses in vitro. Thus, oral rinsing using these might be effective in preventing COVID-19.

5 Nov 2020

Novel insights on a common protein could have broad biomedical applications

A new University of Colorado Boulder-led study sheds light on a protein key to controlling how cells grow, proliferate and function and long implicated in tumor development.

4 Nov 2020

Computational study reveals SARS-CoV-2 spike protein structural stability

Using dynamic contact maps and energy differences between different conformations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (or S-protein), an international team of researchers have recently published an article on the bioRxiv preprint server showing the different stable conformations of the spike protein.

4 Nov 2020

An analysis of genetic diversity of D614G mutation in SARS-CoV-2

A new study published in the preprint server bioRxiv in November 2020 reports that the effect of the mutation is minimal, in terms of pathogenicity or altered response to neutralizing antibodies elicited against the native virus strain.

4 Nov 2020

D614G mutation enhances stability of SARS-CoV-2 spike protein

A new study, published on the preprint server bioRxiv in November 2020 by researchers at the Indian Institute of Science, has explored this issue further. The researchers have found that this mutation is associated with structural and energetic changes that cause this spike variant to become more available during infection, thus rendering the associated strain more infective.

4 Nov 2020

Study shows brilacidin strongly inhibits SARS-CoV-2 in laboratory cell lines

A recent study by US researchers reveals that brilacidin, a small synthetic molecule with peptide-like properties, exerts potent in vitro antiviral activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – both as a standalone treatment and in combination with FDA-approved remdesivir. The study is currently available on the bioRxiv preprint server.

4 Nov 2020

Discoverey of four SARS-CoV-2 Mpro inhibitors, boceprevir, calpain inhibitors II and XII and GC-376

A team of scientists from the United States has recently revealed that small molecule inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease exhibit potent antiviral activity. These inhibitors show better efficacy when used in combination with antiviral medicine Remdesivir. The study is currently available on the bioRxiv* preprint server.

3 Nov 2020

Evidence of robust and persistent antibodies against SARS-CoV-2

A team of researchers from the Icahn School of Medicine at Mount Sinai, New York, have worked in collaboration to try and answer one of the most baffling questions surrounding the coronavirus disease 19 (COVID-19) pandemic: do antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) last after a primary infection?

3 Nov 2020

Rapid generation of divergent synthetic antibodies against SARS-CoV-2 in a cell-free engineering platform

In a groundbreaking bioRxiv paper, a research group from the Massachusetts Institute of Technology (MIT), Harvard University and Howard Hughes Medical Institute in the US engineered antibodies against the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein by using a novel approach. In doing so, they also identified more than 800 predicted binder families.

3 Nov 2020

Estonian researchers provide clues to control the aggressive nature of SARS-CoV-2

Recent study by Estonian researchers in University of Tartu explains how coronavirus is activated before attacking the cell and what could help to impede that.

2 Nov 2020

SARS-CoV-2 spike D614G variant exhibits enhanced replication and transmissibility

A team of scientists from Switzerland, Germany, and the USA has demonstrated that the S-614G variant can easily bind to the human angiotensin-converting enzyme 2 (ACE2), the cellular gateway of SARS-CoV-2. The variant also showed enhanced replication and transmissibility in animal models.

2 Nov 2020

Research shows how remdesivir inhibits SARS-CoV-2 replication

In a recent bioRxiv preprint, a research team from Germany, Goran Kokic et al. study the molecular mechanism of remdesivir-induced stalling of RdRp - using synthetic RNA chemistry, biochemistry, and cryo-electron microscopy.

2 Nov 2020

5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro

Researchers tested 5-amino levulinic acid in vitro in human-derived cells and found it prevents severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Because it is safe and ubiquitous in plants and animals, it could be a potential drug against SARS-CoV-2.

1 Nov 2020

Beetroot peptide may be a good candidate for development of a drug to treat inflammatory diseases

In a recent study, a research group led by Christian Gruber at MedUni Vienna's Institute of Pharmacology isolated a peptide (small protein molecule) from beetroot.

30 Oct 2020

SARS-CoV-2 spike proteins can directly impact the blood-brain barrier

Like a key, SARS-CoV-2 - the virus that causes coronavirus disease 2019 (COVID-19) - attaches to specific molecules on the host cell surface, opening gateways into the cell interior.

30 Oct 2020